Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose PBSC Transplant with Post-Transplant Cyclophosphamide for CGD
NCT02629120Phase 2Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2015
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of peripheral blood stem cells, cyclophosphamide in chronic granulomatous disease (CGD), sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2015; status: active, not recruiting.
02
Drugs
peripheral blood stem cellscyclophosphamide
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT02629120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629120.